Skip to main content
HYFT
NASDAQ Life Sciences

MindWalk Delivers 46% Revenue Growth and Halves Its Net Loss in Fiscal 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.4
Mkt Cap
$67.265M
52W Low
$0.99
52W High
$3.246
52W Position info
41% above low
Off High info
57% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

HYFT sits 41% above its 52-week low of $0.99.

Summary

MindWalk Holdings Corp. reported fiscal 2026 revenue of C$15.6 million, up 46% year-over-year, with gross margin expanding to 59% and net loss narrowing to C$13.9 million. The company also announced its first recurring platform revenue, a share repurchase program, and organic Nasdaq compliance restoration.


Key Events · Earnings and Guidance · HYFT

  • Revenue Surges 46% to C$15.6M

    Full-year revenue grew 46% to C$15.6 million, with Q4 revenue up 50% to C$4.1 million, driven by the company's Bio-Native AI platform.

  • Gross Margin Expands to 59%

    Gross profit rose 60% to C$9.1 million, expanding gross margin by 4.9 percentage points to 58.8%, reflecting improved operational efficiency.

  • Net Loss Narrows by Over Half

    Net loss from continuing operations improved 54% to C$15.1 million, aided by the non-recurrence of C$22.7 million in prior-year non-cash impairment and amortization charges.

  • First Recurring Platform Revenue Secured

    MindWalk signed its first two contracted, recurring enterprise LensAI agreements during the year, marking the first recurring platform revenue in company history.


Analysis · HYFT · Life Sciences

A breakout year is taking shape: revenue surged 46% to C$15.6 million, gross margin expanded to 59%, and the net loss was cut by more than half. The company also secured its first recurring platform revenue, regained Nasdaq compliance without dilutive financing, and authorized a share buyback — all signals that the pivot to Bio-Native AI infrastructure is gaining commercial traction and improving financial health.

At the time of this filing, HYFT was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $0.99 to $3.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HYFT - Latest Insights

HYFT
Jul 22, 2026, 4:54 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.25 info
Change: -$0.1714 (-12%) info
Market Cap: $67.265M info
HYFT
Jul 06, 2026, 10:10 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $1.25 info
Change: -$0.325 (-21%) info
Market Cap: $67.265M info
HYFT
Jul 01, 2026, 9:54 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $1.25 info
Change: -$0.340 (-21%) info
Market Cap: $67.265M info
HYFT
Jun 10, 2026, 9:43 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $1.25 info
Change: -$0.550 (-31%) info
Market Cap: $67.265M info
HYFT
Jun 02, 2026, 10:32 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.84
Real-time Price: $1.25 info
Change: -$0.590 (-32%) info
Market Cap: $67.265M info